Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib or placebo with pemetrexed/cisplatin for initial treatment of nonsquamous NSCLC
2014-001436-10Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ruxolitinib arm with Placebo arm (2 arms). Primary endpoint: Safe and tolerable dose of ruxolitinib in combination with pemetrexed/cisplatin. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-001436-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001436-10.